Select Publications
Cavo M et al. Bortzomib (Velcade)-thalidomide-dexamethasone (VTD) vs thalidomide-dexamethasone (TD) in preparation for autologous stem-cell (SC) transplantation (ASCT) in newly diagnosed multiple myeloma (MM). Proc ASH 2007. Abstract 73.
Facon T et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients
with multiple myeloma (IFM 99-06): A randomised trial. Lancet 2007;370(9594):1209-18. Abstract
Hulin C et al. Comparison of melphalan-prednisone-thalidomide (MP-T) to melphalan-prednisone (MP) in patients 75 years of age or older with untreated multiple myeloma (MM). Preliminary results of the randomized, double-blind, placebo controlled IFM 01-01 trial. Proc ASCO 2007;Abstract 8001.
Jagannath S et al. A phase II study of bortezomib (Velcade®), cyclophosphamide (Cytoxan®), thalidomide (Thalomid®) and dexamethasone as first-line therapy for multiple myeloma. Proc ASH 2007;Abstract 188.
Kumar S et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007;21:(9):2035-42. Abstract
Mazumder A et al. Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia 2008;22(6):1280-1. Abstract
Palumbo A et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: Updated results of a randomized, controlled trial. Blood 2008;[Epub ahead of print]. Abstract
Rajkumar SV et al. Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma
(E4A03): A trial coordinated by the Eastern Cooperative Oncology Group. Proc ASCO 2007;Abstract 8025.
Rajkumar SV et al. A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): A trial coordinated by the Eastern Cooperative Oncology Group. Proc ASH 2007;Abstract 74.
Richardson PG et al. Safety and efficacy of lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: A phase 1/II study. Proc ASCO 2008. Abstract 8520
San-Miguel JF et al. MMY-3002: A phase 3 study comparing bortezomib-melphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myeloma. Proc ASH 2007;Abstract 76.
Wang M et al. Rapid control of previously untreated multiple myeloma with bortezomib-thalidomide-dexamethasone followed by early intensive therapy. Proc ASH 2005;Abstract 784.
| Table of Contents | Top of Page |
EDITOR
Neil Love, MD
INTERVIEWS
Steven D Gore, MD
- Select publications
Michael J Keating, MB, BS
- Select publications
William I Bensinger, MD
- Select publications
Fredrick B Hagemeister, MD
- Select publications
